Matthew J. Zirwas

Dermatology

5300 Far Hills Avenue
Dayton, OH 45429

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 136 publications

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL.

Journal: The Journal of dermatological treatment

Published: August 07, 2026

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

Journal: The Journal of dermatological treatment

Published: June 11, 2026

What Dermatology Residents Need to Know About Joining Group Practices.

What Dermatology Residents Need to Know About Joining Group Practices.

Journal: Cutis

Published: March 16, 2026

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.

Journal: Dermatology and therapy

Published: November 24, 2025

Healthcare Resource Utilization and Economic Burden Across Clinical Phenotypes of Moderate-to-Severe Atopic Dermatitis in United States Dermatology Facilities.

Healthcare Resource Utilization and Economic Burden Across Clinical Phenotypes of Moderate-to-Severe Atopic Dermatitis in United States Dermatology Facilities.

Journal: Dermatology and therapy

Published: October 10, 2025

Eczema Action Plans: Do They Improve Objective Disease Outcomes?

Eczema Action Plans: Do They Improve Objective Disease Outcomes?

Journal: Clinical and experimental dermatology

Published: August 08, 2025

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 30, 2025

Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study.

Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study.

Journal: Dermatology and therapy

Published: June 20, 2025

The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA).

The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA).

Journal: Dermatology and therapy

Published: May 20, 2025

Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis

Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis

Journal: Journal of drugs in dermatology : JDD

Published: May 06, 2025

Burden of Atopic Dermatitis in Patients Initiating Systemic Therapies in the United States.

Burden of Atopic Dermatitis in Patients Initiating Systemic Therapies in the United States.

Journal: Advances in therapy

Published: April 30, 2025

Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study.

Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study.

Journal: Journal of the American Academy of Dermatology

Published: April 22, 2025

Showing 1-12 of 136

Last Updated: 09/26/2026